Is It Too Late to Buy Sarepta Therapeutics Stock?
Sarepta Therapeutics (NASDAQ: SRPT), a midcap biotech company, was riding high 18 months ago. The company was awaiting a crucial regulatory approval from the U.S. Food and Drug Administration (FDA) while delivering solid financial results.
However, a lot has happened since. Sarepta Therapeutics encountered clinical and regulatory headwinds that dragged down its stock price. Sarepta has not performed well on the stock market over the past year. Can the biotech bounce back, or is investing in the stock no longer worth it today?
Sarepta Therapeutics earned approval for Elevidys, a treatment for Duchenne muscular dystrophy (DMD), last year. DMD is a rare, progressive neuromuscular disease that significantly reduces patients' life expectancies.
Source Fool.com
Sarepta Therapeutics Stock
With 0 Sell predictions and 1 Buy predictions the community sentiment towards the Sarepta Therapeutics stock is not clear.
As a result the target price of 130 € shows a slightly positive potential of 7.17% compared to the current price of 121.3 € for Sarepta Therapeutics.
